YXYuanguang Xu

Yuanguang Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuanguang Xu has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • I. I. Fabrikant

    5 shared publications
  • Cheng‐Shie Wuu

    Department of Radiation Oncology, Columbia University, New York, New York 10032

    3 shared publications
  • Marek J. Maryanski

    Department of Radiation Oncology, Columbia University, New York, New York 10032 and MGS Research Inc., Madison, Connecticut 06443

    3 shared publications
  • C.D. Elliston

    Columbia University, College of Physicians and Surgeons, Department of Radiation Oncology, New York, NY

    2 shared publications
  • C.S. Wuu

    Columbia University, College of Physicians and Surgeons, Department of Radiation Oncology, New York, NY

    2 shared publications
  • Cheng-Shie Wuu

    Department of Radiation Oncology, Columbia University, New York, NY 10032, USA

    2 shared publications

Latest Publications

  • Failure Modes and Effects Analysis (FMEA): Based Quality Management Program for Stereotactic Radiosurgery

    by Y. Xu, J. Bhatnagar, G. Bednarz, J.C. Flickinger, Y. Arai, J. Vacsulka, W. Feng, E. Monaco, A. Niranjan, L.D. Lunsford, et al.

  • Evaluation of Tumor Progression and Detection of New Tumors during Repeat Gamma Knife® Stereotactic Radiosurgery Utilizing the Co-Registration Tool in Leksell Gamma Plan®: Technical Note

    by Edward A. Monaco Iii, Jagdish P. Bhatnagar, Yuanguang Xu, Yoshio Arai, Ajay Niranjan, M. Saiful Huq, L. Dade Lunsford

    Background: Repeat Gamma Knife stereotactic radiosurgery (GKSR) procedures are becoming common, especially for brain metastases. It is important to identify tumors requiring treatment at repeat GKSR and it can be challenging to distinguish treated tumors, tumor progression and new tumors. Using the image co-registration tool within the Leksell Gamma Plan software, we developed a technique to aid in the identification of tumors needing treatment. Objectives: The objective was to explore a new co-registration technique to identify tumors requiring treatment at repeat GKSR procedures. Methods: Ten patients who underwent repeat GKSR for brain metastases were identified. Contrast-enhanced volumetric T1 magnetic resonance images (MRI) from the previous GKSR were co-registered with the new images and the resulting two-color format image was used to evaluate tumor status. Results: Using the co-registered images, tumors were characterized as: resolved, regressed, stable, larger or new. Overall, 13.6% of tumors completely resolved, 26.2% regressed, 13.1% remained stable, while 7.9% progressed. Thirty-nine percent of tumors were new. Conclusions: The co-registration technique makes clinically relevant changes conspicuous on MRI. It distinguishes between tumors potentially requiring treatment and those that have been treated successfully. It can be used with tumors other than metastases and for evaluating tumor response at follow-up.


  • Long‐term stability of the Leksell Gamma Knife® Perfexion™ patient positioning system (PPS)

    by J. Novotny, J. P. Bhatnagar, Y. Xu, M. S. Huq

    Purpose:: To assess the long‐term mechanical stability and accuracy of the patient positioning system (PPS) of the Leksell Gamma Knife® Perfexion™ (LGK PFX).Methods:: The mechanical stability of the PPS of the LGK PFX was evaluated using measurements obtained between September 2007 and June 2011. Three methods were employed to measure the deviation of the coincidence of the radiological focus point (RFP) and the PPS calibration center point (CCP). In the first method, the onsite diode test tool with single diode detector was used together with the 4 mm collimator on a daily basis. In the second method, a service diode test tool with three diode detectors was used biannually at the time of the routine preventive maintenance. The test performed with the service diode test tool measured the deviations for all three collimators 4, 8, and 16 mm and also for three different positions of the PPS. The third method employed the conventional film pin‐prick method. This test was performed annually for the 4 mm collimator at the time of the routine annual QA. To estimate the effect of the patient weight on the performance of the PPS, the focus precision tests were also conducted with varying weights on the PPS using a set of lead bricks.Results:: The average deviations measured from the 641 daily focus precision tests were 0.1 ± 0.1, 0.0 ± 0.0, and 0.0 ± 0.0 mm, respectively, for the 4 mm collimator in the X (left/right of the patient), Y (anterior/posterior of the patient), and Z (superior/inferior of the patient) directions. The average of the total radial deviations as measured during ten semiannual measurements with the service diode test tool were 0.070 ± 0.029, 0.060 ± 0.022, and 0.103 ± 0.028 mm, respectively for the central, long, and short diodes for the 4 mm collimator. Similarly, the average total radial deviations measured during the semiannual measurements for the 4, 8, and 16 mm collimators and using the central diode were 0.070 ± 0.029, 0.097 ± 0.025, 0.159 ± 0.028 mm, respectively. The average values of the deviations as obtained from the five annual film pin‐prick tests for the 4 mm collimator were 0.10 ± 0.06, 0.06 ± 0.09, and 0.03 ± 0.03 mm for the X, Y, Z stereotactic directions, respectively. Only a minor change was observed in the total radial deviations of the PPS as a function of the simulated patient weight up to 202 kg on the PPS.Conclusions:: Excellent long‐term mechanical stability and high accuracy was observed for the PPS of the LGK PFX. No PPS recalibration or any adjustment in the PPS was needed during the monitored period of time. Similarly, the weight on the PPS did not cause any significant disturbance in the performance of the PPS for up to 202 kg simulated patient weight.


  • Radiosurgery for benign tumors of the spine using the Synergy S with cone-beam computed tomography image guidance

    by Peter C. Gerszten, Stephanie Chen, Mubina Quader, Yuanguang Xu, Josef Novotny, John C. Flickinger

    Object: There is a growing body of evidence to support the safe and effective use of spine radiosurgery. However, there is much less experience regarding the use of radiosurgery for the treatment of benign as opposed to malignant spine tumors. This study represents an evaluation of, and reporting on, the technical aspects of using a dedicated radiosurgery system for the treatment of benign spine tumors. Methods: Forty-five consecutive benign spine tumors were treated using the Elekta Synergy S 6-MV linear accelerator with a beam modulator and cone-beam computed tomography (CBCT) image guidance technology for target localization. The study cohort included 16 men and 29 women, ranging in age from 23 to 88 years (mean age 52 years). There were 14 cervical, 12 thoracic, 14 lumbar, and 5 sacral tumors. Forty-one lesions (91%) were intradural. The most common histological types of tumor were schwannoma, neurofibroma, and meningioma. Indications for radiosurgery included primary treatment in 24 cases (53%) and treatment of recurrent or residual tumor after open resection in 21 cases (47%). Results: No subacute or long-term spinal cord or cauda equina toxicity occurred during the follow-up period (median 32 months). The mean maximum dose received by the gross tumor volume (GTV) was 16 Gy (range 12–24 Gy) delivered in a single fraction in 39 cases. The mean lowest dose received to the GTV was 12 Gy (range 8–16 Gy). The GTV ranged from 0.37 to 94.5 cm3 (mean 13.7 cm3, median 5.9 cm3). In the majority of cases, a planning target volume expansion of 2 mm was employed (38 cases; 84%). The mean maximum point dose delivered to the spinal cord was 8.7 Gy (range 4–11.5 Gy); the mean volume of the spinal cord that received greater than 8 Gy was 0.9 cm3 (range 0.0–5.1 cm3); and the mean dose delivered to 0.1 cm3 of the spinal cord was 7.5 Gy (range 3–10.5 Gy). The mean maximum point dose delivered to the cauda equina was 10 Gy (range 0–13 Gy); the mean volume of the cauda equina that received greater than 8 Gy was 1.45 cm3 (range 0.0–10.6 cm3); and the mean dose delivered to 0.1 cm3 of the cauda equina was 8 Gy (range 0.5–11 Gy). Conclusions: In this study the authors describe the contouring and prescribed dose techniques used in the treatment planning and delivery of radiosurgery for benign neoplasms of the spine using CBCT image guidance. This technique may serve as an important reference for the performance of radiosurgery when one believes it is clinically indicated as a treatment modality for a benign spine tumor that is associated with both a high safety profile and a strong positive clinical outcome.


  • Predicted Risk of Secondary Lung Malignancies from Breast Radiation Therapy

    by J. Ng, I. Shuryak, Y. Xu, J.N. Shah, I. Deutsch, K.S. Chao, D.J. Brenner, R.J. Burri

  • Sensitivity calibration procedures in optical‐CT scanning of BANG®3 polymer gel dosimeters

    by Y. Xu, Cheng‐Shie Wuu, Marek J. Maryanski

    The dose response of the BANG®3 polymergeldosimeter (MGS Research Inc., Madison, CT) was studied using the OCTOPUS™ laser CT scanner (MGS Research Inc., Madison, CT). Six 17 cm diameter and 12 cm high Barex cylinders, and 18 small glass vials were used to house the gel. The gel phantoms were irradiated with 6 and 10 MV photons, as well as 12 and 16 MeV electrons using a Varian Clinac 2100EX. Three calibration methods were used to obtain the dose response curves: (a) Optical density measurements on the 18 glass vials irradiated with graded doses from 0 to 4 Gy using 6 or 10 MV large field irradiations; (b) optical-CT scanning of Barex cylinders irradiated with graded doses (0.5, 1, 1.5, and 2 Gy) from four adjacent 4 × 4 cm 2 photon fields or 6 × 6 cm 2 electron fields; and (c) percent depth dose (PDD) comparison of optical-CT scans with ion chamber measurements for 6 × 6 cm 2 , 12 and 16 MeV electron fields. The dose response of the BANG®3 gel was found to be linear and energy independent within the uncertainties of the experimental methods (about 3%). The slopes of the linearly fitted dose response curves (dose sensitivities) from the four field irradiations ( 0.0752 ± 3 % , 0.0756 ± 3 % , 0.0767 ± 3 % , and 0.0759 ± 3 % cm − 1 Gy − 1 ) and the PDD matching methods ( 0.0768 ± 3 % and 0.0761 ± 3 % cm − 1 Gy − 1 ) agree within 2.2%, indicating a good reproducibility of the geldose response within phantoms of the same geometry. The dose sensitivities from the glass vial approach are different from those of the cylindrical Barex phantoms by more than 30%, owing probably to the difference in temperature inside the two types of phantoms during gel formation and irradiation, and possible oxygen contamination of the glass vial walls. The dose response curve obtained from the PDD matching approach with 16 MeV electron field was used to calibrate the gel phantom irradiated with the 12 MeV, 6 × 6 cm 2 electron field. Three-dimensional dose distributions from the gel measurement and the Eclipse planning system (Varian Corporation, Palo Alto, CA) were compared and evaluated using 3% dose difference and 2 mm distance-to-agreement criteria.